BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs. The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda,
AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and said it plans to ...
The Brighterside of News on MSN3d
Anti-cancer drug shows incredible promise in human clinical trialsFor decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...
The dual-mechanism drug targets ULBP6, which is secreted by tumor cells and ... while 23ME-01473 slowed the growth of ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
In addition to developing WU-CART-007, a drug candidate in clinical trials for treating relapsed ... T-cell acute ...
"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...
Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all detectable traces of a brain cancer.
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday a $3.5 billion capital investment in the United States, aiming to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback